Mercer Global Advisors
OTLK icon

Mercer Global Advisors’s Outlook Therapeutics OTLK Stock Holding History

Mercer Global Advisors’s Portfolio OTLK Stock Details OTLK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$318 Buy
+200
New +$124 ﹤0.01% 5879

Other funds holding OTLK

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
GWM
Gilpin Wealth Management Denver, Colorado $145M AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SA
Sanctuary Advisors Indianapolis, Indiana $21.6B AUM 28.31% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $171B AUM 85% 1-Year Est. Return

Mercer Global Advisors's OTLK Position: Q2 2026 in Review

Mercer Global Advisors opened a new position in Outlook Therapeutics (OTLK) in Q2 2026: 200 shares worth $318. The stake represents ﹤0.01% of the portfolio and ranks #5879 among its holdings.

50 funds tracked by Wall St. Rank hold OTLK as of Q2 2026.

  • Mercer Global Advisors held 200 shares of Outlook Therapeutics worth $318 as of Q2 2026.
  • Outlook Therapeutics was a new Mercer Global Advisors position in Q2 2026.
  • Outlook Therapeutics made up ﹤0.01% of Mercer Global Advisors's portfolio in Q2 2026, its #5879 holding.
  • 50 funds tracked by Wall St. Rank held Outlook Therapeutics as of Q2 2026.

Based on Mercer Global Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.